INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL EPE

Their core work

The Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) is one of Portugal's leading specialist cancer treatment and research hospitals. They provide oncological care across a wide range of cancer types and conduct clinical research directly embedded in patient care pathways. In H2020 projects, they contribute real-world clinical data, patient cohorts, and oncology expertise — particularly in haematology and the cardiovascular side effects of cancer treatment. Their research role bridges hospital practice and European multi-centre trials, making them a clinical validation partner rather than a basic research lab.

What they specialise in

How they've shifted over time

With only two projects and nearly overlapping start dates (2020 and 2021), a true longitudinal evolution is difficult to trace. Their initial H2020 engagement (QUALITOP) centred on digital quality-of-life monitoring for immunotherapy patients, reflecting a data-collection and patient-experience angle. Their second project (RESILIENCE) shifted toward an interventional cardio-oncology trial — a more clinically active role focused on preventing treatment-induced heart failure. The direction suggests growing confidence in conducting prospective clinical trials, moving from observational digital monitoring toward therapeutic intervention research.

IPOLFG appears to be deepening its focus on cardio-oncology — the growing subspecialty managing heart risks in cancer patients — which positions them well for future trials at the intersection of cardiology and oncology.

How they like to work

IPOLFG participates exclusively as a consortium partner and has never led an H2020 project, which is consistent with their role as a clinical site providing patient access and domain expertise rather than project management capacity. Their participation in two Research and Innovation Actions with 31 distinct partners across 10 countries suggests they are comfortable operating within large, internationally coordinated consortia. They are best approached as a specialist clinical contributor — bringing hospital infrastructure and patient cohorts — rather than as a project coordinator.

IPOLFG has built connections with 31 unique consortium partners across 10 countries through just two projects, suggesting they join well-networked multi-centre European clinical trials. Their reach is broadly European with no apparent regional concentration beyond Portugal.

What sets them apart

IPOLFG is one of very few Portuguese hospitals with active H2020 clinical research participation specifically in cardio-oncology — a subspecialty that most oncology centres treat as secondary. Their combination of haematology patient cohorts and cardiotoxicity research expertise makes them a rare clinical partner for trials that need to track both cancer treatment efficacy and cardiovascular safety simultaneously. For consortium builders needing a Southern European clinical recruitment site with genuine oncology depth, IPOLFG fills a gap that general university hospitals often cannot.

Highlights from their portfolio

• RESILIENCE
  The largest-funded of their two projects (€334,822) and the most clinically distinctive — testing whether remote ischemic conditioning can protect cancer patients' hearts during anthracycline chemotherapy, a direct patient safety intervention with clear commercial and clinical translation potential.
• QUALITOP
  Combines oncology clinical expertise with a digital smart platform for quality-of-life monitoring, demonstrating IPOLFG's ability to bridge hospital practice and digital health data collection in immunotherapy research.